Genetic Engineering & Biotechnology News

NOV1 2018

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link:

Contents of this Issue


Page 36 of 57

Confi dent in your antibody results? Selecting a well-characterized antibody is paramount in order to effi ciently generate impactful results. Our Prestige Antibodies ® , supported by the Human Protein Atlas, off er enhanced validation with additional data to provide the user with confi dence in antibody specifi city and reproducibility. We invite you to explore our extensive off erings. Another reason to trust Prestige Antibodies ® See what's enhanced at Discover enhanced antibody validation © 2018 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, Sigma-Aldrich and the vibrant M are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. 2018-10468 The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - NOV1 2018